Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $67.80 million which beat the analyst consensus estimate of $66.82 million by 1.47 percent. This is a 6.75 percent increase over sales of $63.51 million the same period last year.
BriaCell Therapeutics Announces Pricing Of $5M Registered Direct Offering Of 2,402,935 Common Shares And Warrants Of The Company At A Combined Purchase Price Of $2/Share
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it
